Neuro Advance
Date: Location: Cost:
October 11, 2017 Harvard Medical School - Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115

Starting at $1950

 

Dress Code:
Business Attire

Register

NEURO ADVANCE - October 11, 2017 - DRAFT

Time Agenda
7:00-8:00 am

Registration and Networking Breakfast

8:00-8:30 am

Welcome and Opening Remarks

8:30-9:00 am

Challenges of CNS Translational Research
Jaswant Gidda, CEO, Anagin; Ole Isacson, CSO, Neuroscience, Pfizer; Maria MaccecchiniPresident & CEO, QR Pharma; Timothy PiserCSO, Luc Therapeutics; Darryle SchoeppVP & Head, Neuroscience, Merck

9:00-9:30 am

Financing Innovation in Neuroscience
Adam BruceFounder, TikoMed; Russell Herndon, President & CEO, Hydra BioSciences; Amir TamizProgram Director, Office of Translational Research, NIH
Moderator: Uli HacksellCEO, Cerecor

9:30-10:00 am

Novel Approaches to Alzheimer’s Disease
Leen KawasPresident & CEO, M3 Biotechnology; Jonathan Lewis, CEO, Samus Therapeutics; Min LiSVP & Head, Neuroscience, GlaxoSmithKline;

10:00-10:30 am

Networking Break

10:30-11:00 am

Partnering in Neuroscience
Klaus MendlaGlobal Head, BD&L, CNS, Boehringer Ingelheim; Mark NuttallHead, Immunology & MS BD, Sanofi Genzyme; John Renger, Head, Clinical Research, Purdue Pharma; Cynthia Schwalm, President, North American Commercial Operations, Ipsen; Angelene SimonelloVP Business Operations, Flex Pharma
Moderator: Bob SilvermanHead, Externalized Drug Discovery Partnering, Roche

11:00-11:30 am

Digital Advances in Neurology
Ana MaiquesCEO, Neuroelectrics; Eddie Martucci, Co-Founder & CEO, Akili Interactive

11:30-12:00 pm

Advances in Neuromodulation, Neurostimulation, & Neurotrauma
Richard ManganoCSO, Relmada Therapeutics; Corey McCann, CEO, Pear Therapeutics; Lisa McKerracher, CEO, BioAxone bioSciences
Moderator: Elizabeth WooSVP, Flex Pharma

12:00-1:00 pm

Networking Lunch

1:00-1:30 pm

Stem Cell and Gene Therapy Approaches to CNS Disorders
Marc Beer, Chairman, Minerva Neurosciences; Florian EichlerDirector, Center for Rare Neurological Diseases, Massachusetts General Hospital; Ole Isacson, CSO, Neuroscience Research, Pfizer; Mike Panzara, Franchise Lead, Neurology, WAVE Life Sciences
Moderator: PJ AnandCEO, Alcyone Life Sciences

1:30-2:00 pm

Advances in Neurodegenerative and Neuromuscular Disorders
Rick Batycky
, Chief Technology Officer, Acorda Therapeutics; Paul Bolno, President & CEO, WAVE Life Sciences; Seward RutkoveChief, Neuromuscular Diseases, Beth Israel Deaconess Medical Center; Eric SchaefferSenior Director, Neuroscience External Innovation, Johnson & Johnson; Christoph Westphal, CEO, Flex Pharma
Moderator: Peter LansburyCSO, Lysosomal Therapeutics

2:00-2:30 pm

Advances in Psychiatry
Remy LuthringerPresident & CEO, Minerva Neuroscience; Ron Marcus, CMO, Head, Regulatory, Cerecor; Tony McKinneyPresident & CEO, Neurovance; Alex TkachenkoCEO, BlackThorn Therapeutics
Moderator: Elliot EhrichEVP & CMO, Alkermes

2:30-2:50 pm

Genetics of Neurology & Psychiatry
Gerhard Koenig, CEO, Quartet Medicine; Jens WendlandR&D Lead, Nestle Health Science
Moderator: Kiran ReddyVenture Partner, Clarus Ventures

2:50-3:20 pm

Networking Break

3:20-3:50 pm

Addressing Pain and Addiction
Danguole Altman
, President & CEO, Vapogenix; Elliot Ehrich, EVP, R&D, CMO, Alkermes

3:50-4:20 pm

Advances in Parkinson's Disease
Kees BeenCEO, Lysosomal Therapeutics; Jesse CedarbaumVP, Neurology Discovery & Development, Biogen; Spyros PapapetropoulosVP, Neurodegenerative Diseases, Teva; Ken RhodesCSO, Yumanity; Serge Stankovic, EVP, Head of R&D, ACADIA Pharmaceuticals
Moderator: Ivana Magovcevic-Liebisch, SVP & Head, Global Business Development, Teva

4:20-4:50 pm

Fireside Chat

4:50-6:00 pm

Cocktails and Hors d'oeuvres

Supporting Sponsors: (see all sponsors)

<